None listed
Conditions
Brief summary
High dose magnesium administered intravenously is often utilized in the management of atrial fibrillation with a fast heart rate. Randomised controlled trials have shown conflicting results in regards to its efficacy. We aim to further examine the relationship between the heart rate and magnesium therapy in patients presenting to a Melbourne based Emergency Department with 'fast' atrial fibrillation. We are primarily interested in finding out whether Magnesium therapy aids the reduction of heart rate and our secondary endpoints include; reversion to sinus (normal) rhythm, time to achieve target heart rate, number of additional treatments required to achieve heart rate target, length of stay in emergency department, rate of inpatient hospital admission and 30 day mortality and readmission rates.
Interventions
Following randomisation, there shall be two groups as detailed below.
1. Intervention Arm – Shall receive a single intravenous administration of 20mmol of Magnesium Sulfate in 100mls of normal 0.9% saline over 30 minutes.
2. Placebo Arm – Shall receive a single intravenous administration of 100mls of 0.9% normal saline over 30 minutes.
The above interventions shall not be personalised, this is a randomised controlled study design trial and patients will all be required to sign a patient inf
Following randomisation, there shall be two groups as detailed below. 1. Intervention Arm – Shall receive a single intravenous administration of 20mmol of Magnesium Sulfate in 100mls of normal 0.9% saline over 30 minutes. 2. Placebo Arm – Shall receive a single intravenous administration of 100mls of 0.9% normal saline over 30 minutes. The above interventions shall not be personalised, this is a randomised controlled study design trial and patients will all be required to sign a patient information and consent form detailing participant involvement, risks and study objectives.
Sponsors
Eastern Health Foundation
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Greater than or equal to 18 years of age 2. ECG at presentation to Emergency Department greater than or equal to a ventricular rate of 120 3. Presenting complaint attributable to atrial fibrillation 4. Able to give informed consent
Exclusion criteria
1. Haemodynamically instability, in this study, defined as Systolic Blood Pressure less than 90mmHg 2. Suspected acute myocardial infarction 3. Overt sepsis suspected by treating clinician 4. Known renal impairment (egfr <30)
Outcome results
None listed